Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Series C; Series D
Portfolio 35
| Date | Name | Website | Total Raised | Location |
| 09.07.2025 | Neuros Med... | neurosmedical.com | $144.5M | United Sta... |
| 20.05.2024 | Miach Orth... | miachortho.com | $60M | United Sta... |
| 24.12.2023 | serpexmedical.mystrikingly.com | - | - | |
| 15.03.2023 | Shoulder I... | shoulderinnovations.com | $107.6M | United Sta... |
| 14.05.2022 | XII Medica... | xiimedical.com | $30M | United Sta... |
| 12.03.2022 | Nalu Medic... | nalumed.com | $299M | United Sta... |
| 29.01.2022 | PetDx | petdx.com | $62M | United Sta... |
| 10.10.2021 | Devoro Med... | devoromedical.com | - | - |
| 30.07.2021 | uLab Syste... | ulabsystems.com | $60.5M | United Sta... |
| 14.07.2016 | Endotronix | endotronix.com | $159M | United Sta... |
Show more
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Tony | Natale, M.... | - | - | - | - | |
| - | Eric | H. Sillman | - | - | - | - |
Mentions in press and media 20
| Date | Title | Description |
| 16.09.2025 | ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Mig... | MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its ... |
| 14.07.2025 | Breakthrough Funding Fuels Amputee Pain Revolution | Neuros Medical secured $56 million in Series D funding. EQT Life Sciences led the investment round. This substantial capital accelerates the U.S. commercialization of Altius®, a groundbreaking system. Altius® is FDA-approved. It delivers no... |
| 09.07.2025 | Neuros Medical Raises $56M in Series D Funding | Neuros Medical, Inc., an Aliso Viejo, CA-based maker of the Altius® Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain, raised $56m in Series D financing round. Th... |
| 15.10.2024 | ShiraTronics: A New Dawn for Chronic Migraine Sufferers | Chronic migraines are like shadows that loom over millions, darkening their days and stealing their joy. For those who suffer, the search for relief can feel like an endless journey through a fog. Enter ShiraTronics, a beacon of hope in thi... |
| 09.10.2024 | ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine | Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage medical ... |
| 12.03.2024 | Venus Concept Launches “NEXThetics” Program | New Venus AI Event Series Focused on Enhancing Customer Education and Training TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic ... |
| 07.01.2021 | Cortica Raises $60M to Expand Comprehensive Autism Care Model Nationwide | What You Should Know: – Cortica, Inc. (“Cortica”), a San Diego, CA-based tech-enabled clinical services for autism and other neurodevelopmental conditions, announced it has raised $60 million in financing to further its mission to transform... |
| 19.02.2020 | Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial | LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal ... |
| 01.10.2019 | Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution | LISLE, IL – Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The ... |
| 14.09.2018 | Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure | Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health... |
Show more